+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immunotherapy Drugs Market by Therapy Type, Indication, Route of Administration, End User, Mechanism of Action - Global Forecast to 2030- Product Image
Immunotherapy Drugs Market by Therapy Type, Indication, Route of Administration, End User, Mechanism of Action - Global Forecast to 2030- Product Image
Sale

Immunotherapy Drugs Market by Therapy Type, Indication, Route of Administration, End User, Mechanism of Action - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889000
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Immunotherapy Drugs Market grew from USD 196.96 billion in 2024 to USD 222.59 billion in 2025. It is expected to continue growing at a CAGR of 12.41%, reaching USD 397.54 billion by 2030.

Unveiling the Promise of Immunotherapy in Oncology

The landscape of cancer treatment is undergoing a paradigm shift as immunotherapy emerges as a powerful modality that empowers the patient’s own immune system to recognize and destroy malignant cells. This revolutionary approach builds upon decades of scientific discovery, from initial observations of immune surveillance to recent breakthroughs in cellular engineering. As biological mechanisms become better understood, therapies that harness T cell activation, monoclonal antibodies, and oncolytic viruses are transforming previously intractable malignancies into treatable conditions.

This executive summary synthesizes the latest trends, key drivers, and critical challenges shaping the immunotherapy drugs market. It is designed to inform strategic decision-makers across pharmaceutical companies, biotech innovators, healthcare providers, and investors seeking to navigate a rapidly evolving environment. Readers will gain clarity on technological advancements, regulatory developments, segmentation dynamics, regional differentiators, corporate strategies, and actionable recommendations. By presenting a cohesive narrative, this document highlights both the immense promise and the practical complexities of bringing next-generation immunotherapies to patients worldwide.

Redefining Cancer Treatment through Technological and Scientific Advances

Scientific innovation and patient-centric approaches are converging to redefine the oncology treatment landscape. In recent years, checkpoint inhibitors targeting CTLA-4, PD-1, and PD-L1 pathways have demonstrated sustained remissions in a spectrum of solid and hematologic cancers. Concurrently, advancements in adoptive cell therapies-most notably CAR-T cell engineering-have unlocked unprecedented clinical responses in refractory leukemias and lymphomas. These therapies exemplify the transformative power of precision immunomodulation.

Beyond single-agent successes, the field is embracing combination strategies that integrate vaccines, cytokines, and oncolytic viruses to overcome resistance mechanisms and enhance durability. Data analytics and artificial intelligence are being deployed to identify optimal patient cohorts, predict safety profiles, and streamline trial design. At the same time, regulatory frameworks are adapting to expedite approval pathways while maintaining rigorous safety standards. This convergence of scientific breakthroughs, digital innovation, and evolving policy is propelling immunotherapy from a niche frontier toward mainstream oncology practice.

Navigating the Repercussions of New Tariff Policies on Therapeutic Supply Chains

In 2025, the implementation of revised tariff measures on biologic imports is altering cost structures across the immunotherapy value chain. Critical raw materials-including viral vector components, recombinant proteins, and specialized cell culture reagents-are now subject to increased duties, impacting manufacturers’ production expenses. These incremental costs have reverberated through contract development and manufacturing organizations, prompting some developers to reassess their supplier portfolios and explore domestic sourcing strategies.

Pharmaceutical companies are responding by optimizing supply chain logistics, consolidating procurement, and engaging proactively with policymakers to mitigate adverse effects on patient access. Meanwhile, rising import costs have intensified interest in regional manufacturing hubs, particularly in markets with established biotech infrastructures. Over the long term, this tariff landscape may catalyze strategic partnerships and localized investment, reshaping how immunotherapeutic agents are produced and delivered to global markets.

Decoding Market Segmentation for Precision Immunotherapy Strategies

A nuanced comprehension of market segmentation is essential for aligning product development and commercialization strategies with specific clinical and logistical needs. When evaluating therapy types, the spectrum extends from adoptive cell therapies, featuring CAR-T, NK cell, and TCR-T modalities, to cancer vaccines encompassing dendritic cell, DNA, and peptide platforms. Checkpoint inhibition further subdivides into CTLA-4, PD-1, and PD-L1 inhibitors, while cytokine therapies leverage colony stimulating factors, interferons, and interleukins. Oncolytic virus treatments are categorized by viral origin, including adenovirus-, herpesvirus-, and reovirus-based constructs.

Clinical indications span hematologic malignancies and solid tumors alike. In blood cancers, the focus lies on acute lymphoblastic and myeloid leukemias, chronic lymphocytic leukemia, and diverse lymphomas. Breast cancer efforts differentiate between hormone receptor positive and triple negative subtypes, while lung oncology addresses both non-small cell and small cell variants. Melanoma research covers cutaneous and uveal forms, each demanding tailored immunologic approaches.

Route of administration plays a pivotal role in therapeutic efficacy and patient experience, with treatments delivered intratumorally for localized immune activation, intravenously for systemic distribution, or subcutaneously to balance convenience and pharmacokinetics. The end user profile ranges from large hospitals equipped for complex cell handling to specialized oncology clinics and dedicated treatment centers that manage advanced regimens.

Mechanistic insights reveal distinctions among active immunotherapy, such as cancer vaccines and viral therapies designed to evoke de novo immune responses; passive immunotherapy, exemplified by adoptive cell transfer, checkpoint blockade, and monoclonal antibodies; and combination regimens that marry these approaches to amplify antitumor activity. By dissecting these layers of segmentation, stakeholders can prioritize resource allocation, anticipate regulatory hurdles, and tailor value propositions to diverse healthcare settings.

Regional Dynamics Shaping the Global Immunotherapy Arena

The Americas maintain a dominant position in the immunotherapy arena, driven by robust R&D investment, advanced clinical trial networks, and a receptive regulatory environment. Leading institutions and biopharmaceutical firms collaborate to expedite innovation from bench to bedside, while patients benefit from early access through expanded programs.

In Europe, the Middle East, and Africa, heterogeneous healthcare systems and variable reimbursement frameworks shape adoption rates. While Western European markets embrace high-cost biologic therapies, emerging regions in the Middle East and North Africa are establishing supportive policies to improve availability and build local expertise. Cross-border collaborations within this geography are fostering knowledge exchange and capacity building.

Asia-Pacific demonstrates rapid market uptake, underpinned by large patient populations, government incentives for biotechnology, and expanding manufacturing capabilities. Countries such as China, Japan, and South Korea are home to significant immunotherapy pipelines, with governments streamlining approval processes and funding academic partnerships. This region’s growth trajectory underscores its increasing role as both a development hub and a major consumer market.

Competitive Landscape and Strategic Positioning of Leading Innovators

The competitive landscape is defined by a blend of established pharmaceutical leaders and agile biotech innovators. Companies with pioneering CAR-T therapies continue to refine manufacturing processes and pursue label expansions, while checkpoint inhibitor originators are investing heavily in next-generation biologics with improved safety and efficacy profiles. Similarly, firms specializing in oncolytic viruses are exploring novel delivery vectors and combination regimens to enhance tumor selectivity.

Strategic alliances and licensing agreements abound, as organizations leverage complementary capabilities to accelerate pipeline progression. Partnerships between global players and regional developers are bridging resource gaps and enhancing market access. Concurrently, mergers and acquisitions are reshaping the hierarchy of influence, enabling companies to integrate cell therapy platforms, expand geographic reach, and consolidate manufacturing capacity.

Beyond therapeutic pipelines, leading organizations differentiate through investment in digital health solutions that support patient monitoring, real-world evidence collection, and personalized treatment planning. Companies that successfully integrate these digital assets with their immunotherapy offerings are poised to capture greater market share and establish enduring competitive moats.

Strategic Imperatives for Leadership in Immunotherapy Development

Leaders in the immunotherapy sector should prioritize investments in automated, scalable manufacturing systems to reduce per-dose costs and mitigate quality variability. Establishing geographically distributed production sites will not only buffer against supply chain disruptions but also address tariff-driven cost pressures by localizing key operations.

To accelerate clinical progress, organizations must forge robust partnerships with academic institutions and contract research organizations. Collaborative trial designs that incorporate adaptive protocols and biomarker-driven patient selection can optimize resource utilization and enhance regulatory engagement. Engaging with payers early to demonstrate cost-effectiveness and real-world value will facilitate reimbursement pathways and streamline market entry.

Embracing digital tools for remote patient monitoring and data analytics will empower real-time insights into safety and efficacy, fostering iterative improvements in trial execution. Finally, cultivating patient advocacy networks and transparent communication channels will strengthen trust, improve trial enrollment, and support long-term therapy uptake.

Rigorous Methodological Framework Underpinning the Analysis

This analysis draws on a multi-tiered research design combining primary and secondary data sources. Expert interviews with leading oncologists, regulatory authorities, and industry executives provided qualitative insights into emerging trends and operational challenges. Secondary research encompassed peer-reviewed journals, regulatory filings, patent databases, and corporate disclosures to establish a factual foundation.

Quantitative data collection involved a comprehensive review of clinical trial registries and drug approval records, ensuring that therapeutic staging and pipeline statuses were accurately tracked. Triangulation methods were applied to validate findings across disparate sources, while rigorous peer review by internal subject matter experts ensured analytical integrity.

The methodology acknowledges limitations inherent in publicly available data and potential shifts in regulatory policy. Nonetheless, continuous updates and ongoing expert engagement have been employed to maintain the relevance and validity of conclusions presented herein.

Synthesizing Insights to Propel Future Oncology Breakthroughs

Immunotherapy is unequivocally reshaping the oncology paradigm, offering new avenues for durable disease control and improved patient outcomes. The convergence of cellular engineering, precision biomarkers, and digital augmentation portends a future in which treatments are tailored to individual tumor profiles and immune landscapes.

Navigating tariff developments, supply chain complexities, and regional disparities will require agile strategies and proactive collaboration across the ecosystem. By leveraging segmentation insights and monitoring competitive maneuvers, stakeholders can allocate resources efficiently and capitalize on emerging pockets of opportunity.

Ultimately, the successful commercialization of next-generation immunotherapies hinges on a deep understanding of scientific innovation, regulatory evolution, and market dynamics. Stakeholders who integrate these dimensions into cohesive strategies will be best positioned to deliver transformative therapies to patients worldwide.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapy Type
    • Adoptive Cell Therapy
      • Car-T Therapy
      • Nk Cell Therapy
      • Tcr-T Therapy
    • Cancer Vaccines
      • Dendritic Cell Vaccines
      • Dna Vaccines
      • Peptide Vaccines
    • Checkpoint Inhibitors
      • Ctla-4 Inhibitors
      • Pd-1 Inhibitors
      • Pd-L1 Inhibitors
    • Cytokines
      • Colony Stimulating Factors
      • Interferons
      • Interleukins
    • Oncolytic Virus Therapy
      • Adenovirus Based
      • Herpesvirus Based
      • Reovirus Based
  • Indication
    • Blood Cancer
      • Acute Lymphoblastic Leukemia
      • Acute Myeloid Leukemia
      • Chronic Lymphocytic Leukemia
      • Lymphoma
    • Breast Cancer
      • Hormone Receptor Positive
      • Triple Negative
    • Lung Cancer
      • NonSmallCell Lung Cancer
      • SmallCell Lung Cancer
    • Melanoma
      • Cutaneous Melanoma
      • Uveal Melanoma
  • Route Of Administration
    • Intratumoral
    • Intravenous
    • Subcutaneous
  • End User
    • Hospitals
    • Oncology Clinics
    • Specialized Centers
  • Mechanism Of Action
    • Active Immunotherapy
      • Cancer Vaccines
      • Oncolytic Virus Therapy
    • Combination Therapies
    • Passive Immunotherapy
      • Adoptive Cell Therapy
      • Checkpoint Inhibitors
      • Monoclonal Antibodies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Novartis AG
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Amgen Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Immunotherapy Drugs Market, by Therapy Type
8.1. Introduction
8.2. Adoptive Cell Therapy
8.2.1. Car-T Therapy
8.2.2. Nk Cell Therapy
8.2.3. Tcr-T Therapy
8.3. Cancer Vaccines
8.3.1. Dendritic Cell Vaccines
8.3.2. Dna Vaccines
8.3.3. Peptide Vaccines
8.4. Checkpoint Inhibitors
8.4.1. Ctla-4 Inhibitors
8.4.2. Pd-1 Inhibitors
8.4.3. Pd-L1 Inhibitors
8.5. Cytokines
8.5.1. Colony Stimulating Factors
8.5.2. Interferons
8.5.3. Interleukins
8.6. Oncolytic Virus Therapy
8.6.1. Adenovirus Based
8.6.2. Herpesvirus Based
8.6.3. Reovirus Based
9. Immunotherapy Drugs Market, by Indication
9.1. Introduction
9.2. Blood Cancer
9.2.1. Acute Lymphoblastic Leukemia
9.2.2. Acute Myeloid Leukemia
9.2.3. Chronic Lymphocytic Leukemia
9.2.4. Lymphoma
9.3. Breast Cancer
9.3.1. Hormone Receptor Positive
9.3.2. Triple Negative
9.4. Lung Cancer
9.4.1. NonSmallCell Lung Cancer
9.4.2. SmallCell Lung Cancer
9.5. Melanoma
9.5.1. Cutaneous Melanoma
9.5.2. Uveal Melanoma
10. Immunotherapy Drugs Market, by Route of Administration
10.1. Introduction
10.2. Intratumoral
10.3. Intravenous
10.4. Subcutaneous
11. Immunotherapy Drugs Market, by End User
11.1. Introduction
11.2. Hospitals
11.3. Oncology Clinics
11.4. Specialized Centers
12. Immunotherapy Drugs Market, by Mechanism of Action
12.1. Introduction
12.2. Active Immunotherapy
12.2.1. Cancer Vaccines
12.2.2. Oncolytic Virus Therapy
12.3. Combination Therapies
12.4. Passive Immunotherapy
12.4.1. Adoptive Cell Therapy
12.4.2. Checkpoint Inhibitors
12.4.3. Monoclonal Antibodies
13. Americas Immunotherapy Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Immunotherapy Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Immunotherapy Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Merck & Co., Inc.
16.3.2. Bristol-Myers Squibb Company
16.3.3. F. Hoffmann-La Roche Ltd
16.3.4. AstraZeneca PLC
16.3.5. Novartis AG
16.3.6. Johnson & Johnson
16.3.7. Gilead Sciences, Inc.
16.3.8. Pfizer Inc.
16.3.9. Sanofi S.A.
16.3.10. Amgen Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. IMMUNOTHERAPY DRUGS MARKET MULTI-CURRENCY
FIGURE 2. IMMUNOTHERAPY DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. IMMUNOTHERAPY DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. IMMUNOTHERAPY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 104. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 105. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 106. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 107. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 108. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 109. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 110. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 112. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 113. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 114. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 115. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 118. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 119. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 120. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 121. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 122. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 123. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 124. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 125. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 126. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 128. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 129. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 130. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 131. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 134. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 135. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 201. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 202. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 203. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 204. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 205. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 206. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 207. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 208. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 209. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 210. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 211. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 212. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 215. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 216. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 217. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 218. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 219. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 220. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 221. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 222. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 223. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 224. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 225. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 226. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 227. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 228. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 231. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 232. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 238. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 239. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 241. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 242. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 243. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 244. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 247. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 248. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 249. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 250. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 251. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 252. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 253. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 254. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 255. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 256. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 257. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 258. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 259. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 260. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 263. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 264. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 265. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 266. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 267. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 268. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 269. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 270. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 271. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 272. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 273. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 274. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 275. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 276. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 279. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 280. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 298. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 300. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 302. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 304. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 306. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 312. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 318. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 320. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 322. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 324. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 326. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 327. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 328. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 329. DENMARK I

Companies Mentioned

The companies profiled in this Immunotherapy Drugs market report include:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Novartis AG
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Amgen Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages193
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 222.59 Billion
Forecasted Market Value ( USD ) by 2030 $ 397.54 Billion
Compound Annual Growth Rate12.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cancer Immunotherapy Drugs Market by Mechanism Of Action, Cancer Type, Treatment Line, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Cancer Immunotherapy Drugs Market by Mechanism Of Action, Cancer Type, Treatment Line, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
Cancer Immunotherapy Drug Discovery Outsourcing Market by Service Type, Therapeutic Modality, Workflow Stage, End User - Global Forecast to 2030 - Product Image

Cancer Immunotherapy Drug Discovery Outsourcing Market by Service Type, Therapeutic Modality, Workflow Stage, End User - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Immunotherapy Drugs Market Size, Share & Trends Analysis Report by Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccine), Indication (Autoimmune Diseases, Infectious Diseases, Cancer), Region, with Growth Forecasts, 2025-2030 - Product Image

Immunotherapy Drugs Market Size, Share & Trends Analysis Report by Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccine), Indication (Autoimmune Diseases, Infectious Diseases, Cancer), Region, with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Immunotherapy Drugs Market (2025 Edition): Analysis By Indication (Cancer, Autoimmune & Inflammatory Diseases, Other Indications), By Drug Type, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Immunotherapy Drugs Market (2025 Edition): Analysis By Indication (Cancer, Autoimmune & Inflammatory Diseases, Other Indications), By Drug Type, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 209 Pages
  • Global
From
Cancer Immunotherapy Market Size, Share & Trends Analysis Report by Product, Application, Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-use, with Growth Forecasts, 2025-2030 - Product Image

Cancer Immunotherapy Market Size, Share & Trends Analysis Report by Product, Application, Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-use, with Growth Forecasts, 2025-2030

  • Report
  • 110 Pages
  • Global
From

About the Immunotherapy Market

Immunotherapy is a type of treatment used to treat immune disorders, such as allergies, asthma, and autoimmune diseases. It works by stimulating the body's own immune system to fight off disease-causing agents. Immunotherapy drugs are designed to target specific parts of the immune system, such as T-cells, B-cells, and cytokines. These drugs can be used to treat a variety of conditions, including cancer, HIV/AIDS, and rheumatoid arthritis. Immunotherapy drugs are typically administered through injections, infusions, or oral medications. They can also be used in combination with other treatments, such as chemotherapy or radiation therapy. The goal of immunotherapy is to reduce the severity of symptoms and improve the patient's quality of life. The immunotherapy market is a rapidly growing sector of the pharmaceutical industry. Companies in this market are focused on developing new treatments and therapies to treat immune disorders. Some of the major players in this market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.